64,262 Shares in Zai Lab Limited Unsponsored ADR $ZLAB Purchased by Tema Etfs LLC

Key Points

• Tema Etfs LLC acquired 64,262 shares of Zai Lab Limited Unsponsored ADR, valued at approximately $2.32 million, representing a 0.06% ownership stake.
• Zai Lab reported a revenue of $109.98 million for the last quarter, falling short of analysts' expectations of $125.66 million, with an EPS of ($0.37).
• Analysts have set a new average target price of $56.35 for Zai Lab, with six analysts rating the stock as a Buy.

Tema Etfs LLC bought a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 64,262 shares of the company's stock, valued at approximately $2,322,000. Tema Etfs LLC owned about 0.06% of Zai Lab as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of ZLAB. Kingsview Wealth Management LLC lifted its position in Zai Lab by 6.0% during the first quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock valued at $337,000 after buying an additional 529 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Zai Lab during the fourth quarter valued at approximately $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock valued at $1,496,000 after buying an additional 1,200 shares in the last quarter. Walleye Capital LLC lifted its position in Zai Lab by 6.4% during the first quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock valued at $805,000 after buying an additional 1,338 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Zai Lab by 13.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock valued at $453,000 after buying an additional 1,483 shares in the last quarter. 41.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CFO Yajing Chen sold 1,438 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total transaction of $50,933.96. Following the completion of the sale, the chief financial officer owned 16,720 shares in the company, valued at $592,222.40. The trade was a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua L. Smiley sold 6,641 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $36.24, for a total transaction of $240,669.84. Following the sale, the insider owned 76,604 shares of the company's stock, valued at approximately $2,776,128.96. The trade was a 7.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 215,710 shares of company stock worth $7,589,684 in the last ninety days. 4.96% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ZLAB has been the topic of a number of recent research reports. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a research report on Monday, June 30th. Citigroup reaffirmed a "buy" rating and set a $69.00 price target (up from $66.00) on shares of Zai Lab in a research report on Monday, August 11th. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Jefferies Financial Group started coverage on shares of Zai Lab in a research report on Monday, August 25th. They set a "buy" rating and a $52.00 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Zai Lab has an average rating of "Moderate Buy" and an average price target of $56.35.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB traded up $0.88 during midday trading on Monday, reaching $33.10. The company had a trading volume of 378,288 shares, compared to its average volume of 538,751. The stock's fifty day moving average price is $35.68 and its 200-day moving average price is $34.04. The stock has a market capitalization of $3.70 billion, a P/E ratio of -16.23 and a beta of 1.04. Zai Lab Limited Unsponsored ADR has a one year low of $18.60 and a one year high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.37). The business had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.